Another exciting area of personalized medicine is using nanotechnology for gene therapy. Gene therapy involves altering or ...

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that CEPI, the Coalition for Epidemic Preparedness ...

YolTech Therapeutics is set to commence a trial of its in vivo gene editing therapy, YOLT-204, aimed at treating TDT.

SHANGHAI, China I January 20, 2025 I YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the ...

YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for YOLT-204, an investigational therapy for the ...

The study will focus on testing lipid-based nanoparticles that encapsulate ribonucleic acid (RNA) for delivery into cells.

A couple of University of Nebraska professors have launched a startup company with the goal of bringing to market an ...

Nebraska researchers introduce Minovacca, pioneering programmable milk exosomes for targeted therapeutic delivery, offering ...

Arbutus Biopharma Corporation (NASDAQ: ABUS) has unveiled its strategic objectives for 2025 alongside an encouraging ...

How can we ensure that life-saving drugs or genetic therapies reach their intended target cells without causing harmful side ...

MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio's proprietary self-amplifying ...